Changing the course of Metabolic-Cardio-Renal risk in T2DM: Role of SGLT-2i + DPP-4i

Empagliflozin/ linagliptin, a  combination sodium-glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor as an adjunct to diet and exercise in adults is an effective treatment in type 2 diabetes patients. 1 In relation to this, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 23 rd November 2020 from 07:00 PM IST onwards. In this webinar, Dr. Ganapathi Bantwal, Dr. Manash Pratim Baruah, and Dr. (Prof.) Saumitra Ray will elucidate on Changing the course of Metabolic-Cardio-Renal risk in T2DM: Role of SGLT-2i + DPP-4i.

We invite you to share your questions which will be answered by the experts at the end of the session. Reference: Kim ES, Deeks ED. Empagliflozin/linagliptin: a review in type 2 diabetes. Drugs. 2015 Sep 1;75(13):1547-57.